B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
    • Subject Terms:
      B-Lymphocytes/*immunology ; COVID-19/*immunology ; COVID-19 Vaccines/*immunology ; SARS-CoV-2/*immunology ; T-Lymphocytes/*immunology; Adult ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; BNT162 Vaccine ; COVID-19/virology ; Enzyme-Linked Immunosorbent Assay/methods ; Female ; Health Personnel ; Humans ; Immunity, Humoral/immunology ; Male ; Spike Glycoprotein, Coronavirus/immunology ; Vaccination/methods
    • Abstract:
      Background: In recent months numerous health care professional acquired COVID-19 at the workplace resulting in significant shortages in medical and nursing staff. We investigated how prior COVID-19 affects SARS-CoV-2 vaccination and how such knowledge could facilitate frugal vaccination strategies.
      Methods: In a cohort of 41 healthcare professionals with (n=14) and without (n=27) previous SARS-CoV-2 infection, we assessed the immune status before, during and after vaccination with BNT162b2. The humoral immune response was assessed by receptor binding domain ELISA and different SARS-CoV-2 neutralisation assays using wildtype and pseudo-typed viruses. T cell immunity against SARS-CoV-2 surface and nucleocapsid peptides were studied using interferon-γ release assays and intracellular flow cytometry. Vaccine-related side effects were captured.
      Findings: Prior COVID-19 resulted in improved vaccine responses both in the B and T cell compartment. In vaccine recipients with prior COVID-19, the first vaccine dose induced high antibody concentrations comparable to seronegative vaccine recipients after two injections. This translated into more efficient neutralisation of virus particles, even more pronounced than expected from the RBD ELISA results. Furthermore, T cell responses were stronger in convalescents and particularly strong against the SARS-CoV-2 nucleocapsid protein.
      Interpretation: Herein, we corroborate recent findings suggesting that in convalescents a single vaccine dose is sufficient to boost adequate in vitro neutralisation of SARS-CoV-2 and therefore may be sufficient to induce adequate protection against severe COVID-19. New spike mutated virus variants render the highly conserved nucleocapsid protein - eliciting strong SARS-CoV-2 specific T cell immunity - an interesting additional vaccine target.
      Funding: Christian Doppler Research Association, Johannes Kepler University Linz.
      Competing Interests: Declaration of Competing Interest TRK and MF are employees of Baxter AG, Vienna, Austria, now part of the Takeda group of companies and have Takeda stock interest. All other authors declare no competing interests.
      (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Covid-19; Humoral response; Pre-existing immunity; SARS-CoV-2; T cell immunity; Vaccination
    • Accession Number:
      0 (Antibodies, Neutralizing)
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
      0 (Spike Glycoprotein, Coronavirus)
      N38TVC63NU (BNT162 Vaccine)
    • Publication Date:
      Date Created: 20210814 Date Completed: 20210914 Latest Revision: 20211204
    • Publication Date:
      20221213
    • Accession Number:
      PMC8358275
    • Accession Number:
      10.1016/j.ebiom.2021.103539
    • Accession Number:
      34391087